 Home > Active Ingredient News > Immunology News > Heidelb: A study of tuberculosis-positive conversion rates in patients with psoriasis treated with adalimus and scuqiyu

Heidelb: A study of tuberculosis-positive conversion rates in patients with psoriasis treated with adalimus and scuqiyu

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

schauer power center

2 4 pentanedione

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Psoriasis is a common immune-mediated disease affecting approximately 2% of the global populati.

Worldwide, tuberculosis (TB) positivity conversion rates have been reported in psoriasis patients treated with biologics, particularly in regions with low tuberculosis ri.

Methods: Patients admitted to West China Hospital of Sichuan University from April 2019 to February 2021 were select.

Results: In the adalimumab group, 5 patients (43%) had tuberculosis negative, and 2 of them developed active tuberculosis within the first 6 mont.

Conclusions: Our data showed that among these psoriasis patients, TB conversion rates were relatively high after a mean course of 113 mont.

We recommend reassessment for tuberculosis after the initial 3 months in patients receiving adalimumab and then semiannual monitoring for the next two yea.

Source: Xiao Y, Chen H, Zou Q The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in Chi.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top Quality 99.9% Ritlecitinib Tosylate Immunoregulation API & Inflammation Inhibitor

CAS No.: 2192215-81-7

Pharmacy Grade; Food Grade

$200-250/G FOB

β-Alanine107-95-9

CAS No.: 107-95-9

$1-1.1/KG FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.